Regenxbio (RGNX) - Market Cap to Earnings

Corporate emblem and logo of REGENXBIO Inc (RGNX)

REGENXBIO Inc. (RGNX) minimizes capital expenditures by outsourcing vector production and testing to third-party contractors, which is evidenced by the asset's market value on the GURU.Markets platform as shown on this chart, where the indicator stands at -2.90. While the business faces stringent regulatory oversight and high development costs, it mitigates these threats by granting other players the rights to use its NAV platform in exchange for royalties.

REGENXBIO Inc - RGNX Price to Earnings Ratio (period 07/04/2022 - 11/16/2026)

Comprehensive metric breakdowns and analytics for regenxbio.com (RGNX)

- current quotes and average value forecast:
- market capitalization indicators:
Comprehensive company analysis:RGNX (Regenxbio)
Brand item of REGENXBIO Inc.

The P/E ratio determines the market value of a single unit of profit, reflecting investor expectations regarding future earnings. This metric compares market capitalization with net income, allowing analysts to assess the degree of overvaluation of an asset through the company's P/E trend. For REGENXBIO Inc. (RGNX), this indicator becomes a critical filter when analyzing gene therapy costs. High development costs and clinical trial risks make this multiple the primary tool for evaluating the issuer's financial stability.

Competing companies

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Solid Biosciences Inc. - Price to Earnings Multiple|Price to Earnings Ratio Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio